Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 4309.44
MASI's Cash-to-Debt is ranked higher than
68% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 2.45 vs. MASI: 4309.44 )
Ranked among companies with meaningful Cash-to-Debt only.
MASI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.49  Med: 513.4 Max: No Debt
Current: 4309.44
Equity-to-Asset 0.68
MASI's Equity-to-Asset is ranked higher than
61% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. MASI: 0.68 )
Ranked among companies with meaningful Equity-to-Asset only.
MASI' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.07  Med: 0.66 Max: 0.81
Current: 0.68
-3.07
0.81
Interest Coverage N/A
MASI's Interest Coverage is ranked higher than
70% of the 226 Companies
in the Global Medical Devices industry.

( Industry Median: 93.54 vs. MASI: N/A )
Ranked among companies with meaningful Interest Coverage only.
MASI' s Interest Coverage Range Over the Past 10 Years
Min: 27.05  Med: N/A Max: No Debt
Current: N/A
Piotroski F-Score: 9
Altman Z-Score: 14.79
Beneish M-Score: -2.85
WACC vs ROIC
8.17%
91.62%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 10/10

vs
industry
vs
history
Operating Margin % 60.58
MASI's Operating Margin % is ranked higher than
100% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. MASI: 60.58 )
Ranked among companies with meaningful Operating Margin % only.
MASI' s Operating Margin % Range Over the Past 10 Years
Min: 14.57  Med: 21.48 Max: 60.58
Current: 60.58
14.57
60.58
Net Margin % 43.28
MASI's Net Margin % is ranked higher than
99% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 1.50 vs. MASI: 43.28 )
Ranked among companies with meaningful Net Margin % only.
MASI' s Net Margin % Range Over the Past 10 Years
Min: 10.4  Med: 13.87 Max: 43.28
Current: 43.28
10.4
43.28
ROE % 86.80
MASI's ROE % is ranked higher than
99% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 2.08 vs. MASI: 86.80 )
Ranked among companies with meaningful ROE % only.
MASI' s ROE % Range Over the Past 10 Years
Min: 17.28  Med: 22.79 Max: 71.96
Current: 86.8
17.28
71.96
ROA % 45.75
MASI's ROA % is ranked higher than
99% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. MASI: 45.75 )
Ranked among companies with meaningful ROA % only.
MASI' s ROA % Range Over the Past 10 Years
Min: 12.07  Med: 16.6 Max: 42.28
Current: 45.75
12.07
42.28
ROC (Joel Greenblatt) % 240.73
MASI's ROC (Joel Greenblatt) % is ranked higher than
99% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 4.02 vs. MASI: 240.73 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MASI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 78.21  Med: 141.81 Max: 277.99
Current: 240.73
78.21
277.99
3-Year Revenue Growth Rate 11.10
MASI's 3-Year Revenue Growth Rate is ranked higher than
72% of the 227 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. MASI: 11.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MASI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -19.3  Med: 12.35 Max: 30.3
Current: 11.1
-19.3
30.3
3-Year EBITDA Growth Rate 73.10
MASI's 3-Year EBITDA Growth Rate is ranked higher than
95% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: 5.60 vs. MASI: 73.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MASI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 10.7 Max: 287.2
Current: 73.1
0
287.2
3-Year EPS without NRI Growth Rate 76.90
MASI's 3-Year EPS without NRI Growth Rate is ranked higher than
91% of the 197 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. MASI: 76.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MASI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -33.8  Med: 8.1 Max: 76.9
Current: 76.9
-33.8
76.9
GuruFocus has detected 4 Warning Signs with Masimo Corp $MASI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MASI's 10-Y Financials

Financials (Next Earnings Date: 2017-05-14 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

MASI Guru Trades in Q1 2016

Joel Greenblatt 13,804 sh (New)
John Hussman 325,000 sh (+160.00%)
Jim Simons 232,700 sh (+4.63%)
Paul Tudor Jones 12,662 sh (+2.94%)
Mario Gabelli 131,400 sh (-0.45%)
Jeremy Grantham 30,800 sh (-0.96%)
Chuck Royce 115,000 sh (-36.81%)
» More
Q2 2016

MASI Guru Trades in Q2 2016

Steven Cohen 73,300 sh (New)
Paul Tudor Jones 13,464 sh (+6.33%)
Joel Greenblatt 14,017 sh (+1.54%)
Chuck Royce 115,000 sh (unchged)
Jeremy Grantham Sold Out
Mario Gabelli 130,200 sh (-0.91%)
John Hussman 268,000 sh (-17.54%)
Jim Simons 143,800 sh (-38.20%)
» More
Q3 2016

MASI Guru Trades in Q3 2016

Joel Greenblatt 27,968 sh (+99.53%)
Steven Cohen 83,700 sh (+14.19%)
Mario Gabelli 130,200 sh (unchged)
Chuck Royce 115,000 sh (unchged)
Paul Tudor Jones 12,982 sh (-3.58%)
John Hussman 200,000 sh (-25.37%)
Jim Simons 78,500 sh (-45.41%)
» More
Q4 2016

MASI Guru Trades in Q4 2016

Columbia Wanger 838,230 sh (New)
Steven Cohen 195,100 sh (+133.09%)
Jim Simons 173,400 sh (+120.89%)
Joel Greenblatt 39,433 sh (+40.99%)
Mario Gabelli 130,000 sh (-0.15%)
John Hussman 102,000 sh (-49.00%)
Chuck Royce 57,300 sh (-50.17%)
Paul Tudor Jones 4,862 sh (-62.55%)
» More
» Details

Insider Trades

Latest Guru Trades with MASI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare: » details
Traded in other countries:3M4.Germany,
Masimo Corp is a medical technology company. The Company develops, manufactures, and markets noninvasive monitoring technologies. Its product includes noninvasive blood constituent and brain and breath monitoring.

Masimo Corp was incorporated in California in May 1989 and reincorporated in Delaware in May 1996. The Company is a medical technology company that develops, manufactures, and markets a variety of noninvasive monitoring technologies. It provides products directly and through distributors and original equipment manufacturers (OEM) partners to hospitals, emergency medical service (EMS) providers, physician offices, veterinarians, long term care facilities and consumers. Its business is Measure-through-Motion and Low-Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its products offering include monitoring blood constituents with an optical signature, optical organ oximetry monitoring, and electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring. In addition, it has also developed Root patient monitoring and connectivity platform, the Radical-7 bedside and portable patient monitor and the Radius-7 wearable wireless patient monitor. It also developed the Patient SafetyNet remote patient surveillance monitoring system, which allows up to 200 patients to be monitored simultaneously and remotely through a PC-based viewing station or by care providers through their pagers, voice-over-IP phones or smartphones. The Company's solutions and related products are based upon its proprietary Masimo SET and rainbow algorithms. It also provides technologies to OEMs in a form factor that is easy to integrate into their patient monitors, defibrillators and infant incubators. It also develops, manufactures and markets patient monitoring technologies that incorporate a monitor or circuit board and sensors, including proprietary single-patient-use, reusable and rainbow ReSposable sensors and patient cables. In addition, it offers remote alarm/monitoring solutions, software and connectivity solutions. Its product components includes Patient Monitoring Solutions including Circuit Boards and Modules, a signal processing apparatus for all Masimo technology platforms, Monitors and Devices, Patient Monitoring and Connectivity Platforms, Sensors, Line Filters and Mainstream Adapters, Remote Alarm and Monitoring Solutions, Proprietary Measurement, and Connectivity; and Consumer Monitoring Solutions including Devices. The Company is subject to U.S. Food, Drug, and Cosmetic Act (FDCA) and the regulations promulgated under that Act, the FDA regulates the design, development, clinical trials, testing, manufacture, packaging, labeling, storage, distribution and promotion of medical devices.

Top Ranked Articles about Masimo Corp

Weekly CEO Sells Highlight: Gentex Corp, Masimo Corp, The Michaels Companies, Boyd Gaming Corp
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: Gentex Corp., Masimo Corp., The Michaels Companies Inc., Boyd Gaming Corp. Read more...

Ratios

vs
industry
vs
history
PE Ratio 16.50
MASI's PE Ratio is ranked higher than
76% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 27.89 vs. MASI: 16.50 )
Ranked among companies with meaningful PE Ratio only.
MASI' s PE Ratio Range Over the Past 10 Years
Min: 10.85  Med: 25.31 Max: 69.65
Current: 16.5
10.85
69.65
Forward PE Ratio 40.98
MASI's Forward PE Ratio is ranked lower than
82% of the 57 Companies
in the Global Medical Devices industry.

( Industry Median: 23.04 vs. MASI: 40.98 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 16.50
MASI's PE Ratio without NRI is ranked higher than
77% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 28.39 vs. MASI: 16.50 )
Ranked among companies with meaningful PE Ratio without NRI only.
MASI' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.85  Med: 25.31 Max: 69.65
Current: 16.5
10.85
69.65
Price-to-Owner-Earnings 13.63
MASI's Price-to-Owner-Earnings is ranked higher than
87% of the 102 Companies
in the Global Medical Devices industry.

( Industry Median: 30.77 vs. MASI: 13.63 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MASI' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.97  Med: 30.95 Max: 160.32
Current: 13.63
8.97
160.32
PB Ratio 8.35
MASI's PB Ratio is ranked lower than
85% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 3.35 vs. MASI: 8.35 )
Ranked among companies with meaningful PB Ratio only.
MASI' s PB Ratio Range Over the Past 10 Years
Min: 3.53  Med: 6.04 Max: 15.19
Current: 8.35
3.53
15.19
PS Ratio 7.09
MASI's PS Ratio is ranked lower than
76% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 3.31 vs. MASI: 7.09 )
Ranked among companies with meaningful PS Ratio only.
MASI' s PS Ratio Range Over the Past 10 Years
Min: 1.77  Med: 3.43 Max: 8.26
Current: 7.09
1.77
8.26
Price-to-Free-Cash-Flow 12.62
MASI's Price-to-Free-Cash-Flow is ranked higher than
83% of the 109 Companies
in the Global Medical Devices industry.

( Industry Median: 29.73 vs. MASI: 12.62 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MASI' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.3  Med: 29.14 Max: 2401.82
Current: 12.62
8.3
2401.82
Price-to-Operating-Cash-Flow 11.88
MASI's Price-to-Operating-Cash-Flow is ranked higher than
78% of the 139 Companies
in the Global Medical Devices industry.

( Industry Median: 20.26 vs. MASI: 11.88 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MASI' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.81  Med: 21.36 Max: 51.39
Current: 11.88
7.81
51.39
EV-to-EBIT 10.44
MASI's EV-to-EBIT is ranked higher than
85% of the 162 Companies
in the Global Medical Devices industry.

( Industry Median: 23.96 vs. MASI: 10.44 )
Ranked among companies with meaningful EV-to-EBIT only.
MASI' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.1  Med: 16.5 Max: 34.5
Current: 10.44
6.1
34.5
EV-to-EBITDA 10.04
MASI's EV-to-EBITDA is ranked higher than
77% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 17.54 vs. MASI: 10.04 )
Ranked among companies with meaningful EV-to-EBITDA only.
MASI' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.7  Med: 14.9 Max: 32.1
Current: 10.04
5.7
32.1
PEG Ratio 0.50
MASI's PEG Ratio is ranked higher than
91% of the 77 Companies
in the Global Medical Devices industry.

( Industry Median: 2.47 vs. MASI: 0.50 )
Ranked among companies with meaningful PEG Ratio only.
MASI' s PEG Ratio Range Over the Past 10 Years
Min: 0.48  Med: 9.26 Max: 617.25
Current: 0.5
0.48
617.25
Shiller PE Ratio 60.22
MASI's Shiller PE Ratio is ranked lower than
60% of the 50 Companies
in the Global Medical Devices industry.

( Industry Median: 54.18 vs. MASI: 60.22 )
Ranked among companies with meaningful Shiller PE Ratio only.
MASI' s Shiller PE Ratio Range Over the Past 10 Years
Min: 20.24  Med: 31.84 Max: 61.53
Current: 60.22
20.24
61.53
Current Ratio 2.30
MASI's Current Ratio is ranked lower than
51% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 2.33 vs. MASI: 2.30 )
Ranked among companies with meaningful Current Ratio only.
MASI' s Current Ratio Range Over the Past 10 Years
Min: 1.35  Med: 2.54 Max: 4.87
Current: 2.3
1.35
4.87
Quick Ratio 1.97
MASI's Quick Ratio is ranked higher than
56% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 1.67 vs. MASI: 1.97 )
Ranked among companies with meaningful Quick Ratio only.
MASI' s Quick Ratio Range Over the Past 10 Years
Min: 1.15  Med: 2.02 Max: 4.34
Current: 1.97
1.15
4.34
Days Inventory 103.24
MASI's Days Inventory is ranked higher than
61% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 125.58 vs. MASI: 103.24 )
Ranked among companies with meaningful Days Inventory only.
MASI' s Days Inventory Range Over the Past 10 Years
Min: 99.78  Med: 106.83 Max: 117.9
Current: 103.24
99.78
117.9
Days Sales Outstanding 53.45
MASI's Days Sales Outstanding is ranked higher than
70% of the 240 Companies
in the Global Medical Devices industry.

( Industry Median: 66.89 vs. MASI: 53.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
MASI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.51  Med: 45.82 Max: 53.45
Current: 53.45
36.51
53.45
Days Payable 49.22
MASI's Days Payable is ranked lower than
55% of the 227 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. MASI: 49.22 )
Ranked among companies with meaningful Days Payable only.
MASI' s Days Payable Range Over the Past 10 Years
Min: 42.89  Med: 62.88 Max: 72.6
Current: 49.22
42.89
72.6

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 3.90
MASI's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: -3.40 vs. MASI: 3.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MASI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -79.8  Med: -1.65 Max: 4.3
Current: 3.9
-79.8
4.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 102.45
MASI's Price-to-Net-Cash is ranked lower than
92% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 15.26 vs. MASI: 102.45 )
Ranked among companies with meaningful Price-to-Net-Cash only.
MASI' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 14.49  Med: 50.39 Max: 290.7
Current: 102.45
14.49
290.7
Price-to-Net-Current-Asset-Value 18.95
MASI's Price-to-Net-Current-Asset-Value is ranked lower than
81% of the 217 Companies
in the Global Medical Devices industry.

( Industry Median: 6.50 vs. MASI: 18.95 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
MASI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 6.27  Med: 10.73 Max: 36.08
Current: 18.95
6.27
36.08
Price-to-Tangible-Book 9.15
MASI's Price-to-Tangible-Book is ranked lower than
79% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 4.19 vs. MASI: 9.15 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MASI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.11  Med: 6.46 Max: 14.94
Current: 9.15
4.11
14.94
Price-to-Intrinsic-Value-Projected-FCF 2.42
MASI's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
57% of the 127 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. MASI: 2.42 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MASI' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.71  Med: 1.75 Max: 3.75
Current: 2.42
1.71
3.75
Price-to-Median-PS-Value 2.07
MASI's Price-to-Median-PS-Value is ranked lower than
88% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 1.07 vs. MASI: 2.07 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MASI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.73  Med: 1.04 Max: 2.07
Current: 2.07
0.73
2.07
Price-to-Peter-Lynch-Fair-Value 0.73
MASI's Price-to-Peter-Lynch-Fair-Value is ranked higher than
89% of the 55 Companies
in the Global Medical Devices industry.

( Industry Median: 1.68 vs. MASI: 0.73 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
MASI' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.53  Med: 0.96 Max: 3.47
Current: 0.73
0.53
3.47
Price-to-Graham-Number 2.59
MASI's Price-to-Graham-Number is ranked lower than
51% of the 131 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. MASI: 2.59 )
Ranked among companies with meaningful Price-to-Graham-Number only.
MASI' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.8  Med: 2.84 Max: 6.61
Current: 2.59
1.8
6.61
Earnings Yield (Greenblatt) % 9.58
MASI's Earnings Yield (Greenblatt) % is ranked higher than
93% of the 339 Companies
in the Global Medical Devices industry.

( Industry Median: -0.81 vs. MASI: 9.58 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MASI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.9  Med: 6.1 Max: 16.4
Current: 9.58
2.9
16.4
Forward Rate of Return (Yacktman) % 24.94
MASI's Forward Rate of Return (Yacktman) % is ranked higher than
87% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 9.01 vs. MASI: 24.94 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MASI' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -31.9  Med: 3.7 Max: 26.1
Current: 24.94
-31.9
26.1

More Statistics

Revenue (TTM) (Mil) $694.6
EPS (TTM) $ 5.65
Beta0.79
Short Percentage of Float5.51%
52-Week Range $39.24 - 96.68
Shares Outstanding (Mil)50.42

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 752 812 887
EPS ($) 2.27 2.58 2.98
EPS without NRI ($) 2.27 2.58 2.98
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for MASI

Headlines

Articles On GuruFocus.com
John Hussman's Top-Performing Stocks Jul 05 2016 
Weekly CEO Sells Highlight: Gentex Corp, Masimo Corp, The Michaels Companies Inc, Boyd Gaming Corp. Jun 13 2016 
BTIM Corp's Top Buys in Q2 2015 Jul 20 2015 
Meridian Funds' Top Five Second Quarter Increases Jul 30 2013 
Weekly CEO Buys Highlight: MDR, MASI, FCH, FGP, FUR Jun 10 2012 
Masimo Corp. CEO Joe Kiani Buys 50,000 Shares Jun 04 2012 
Weekly CEO Buys Highlight: KMI, VGR, SIRO, PNK, MASI Nov 27 2011 
Weekly CEO Buys Highlight: SLM, MASI, ITRI, FLS, PG Nov 05 2011 
Weekly CEO Buys Highlight: MASI, ITRI, FSL, PTP, SLB Oct 29 2011 
Masimo Corp. Reports Operating Results (10-K) Feb 16 2011 

More From Other Websites
Has Masimo Become Too Expensive to Hold? Mar 20 2017
Masimo Announces CE Marking of Rad-97™ Pulse CO-Oximeter® and Connectivity Hub with Noninvasive... Mar 20 2017
Masimo Announces CE Marking of Rad-97™ Pulse CO-Oximeter® and Connectivity Hub with Noninvasive... Mar 20 2017
Masimo (MASI) Up 20.6% Since Earnings Report: Can It Continue? Mar 17 2017
3 Medical Device Stocks to Brave Policy Uncertainty Mar 16 2017
Biogen, LendingClub, IBM, and More: Here’s What Analysts Had to Say About These Five Stocks Mar 16 2017
Masimo downgraded by Piper Jaffray Mar 16 2017
New Study Evaluates the Utility of Masimo SpHb® Monitoring During Liver Transplantation Mar 13 2017
S&P Dow Jones Indices Announces Changes to U.S. Indices and Updates to U.S. Indices Methodology and... Mar 10 2017
Can The Uptrend Continue for Masimo (MASI)? Mar 10 2017
Stocks: Ready for Trump rally rebound or third straight down day and bigger retreat from Dow 21K? Mar 07 2017
Masimo Announces Availability of RD SedLine Brain Sensors Mar 07 2017
Masimo to Present at 29th Annual ROTH Conference Mar 06 2017
Is Masimo (MASI) a Great Growth Stock? Mar 06 2017
Masimo Announces Availability of the RD SedLine® Adult EEG Sensor Mar 06 2017
Stocks today: Snap goes public, Apple flirts with $140, Trump rally sell-off or more records for... Mar 02 2017
Masimo's Stock Is a Great Buy Right Now Feb 28 2017
Masimo to Present at 38th Annual Raymond James Institutional Investors Conference Feb 28 2017
Zacks.com featured highlights: Pool, Walker & Dunlop, Exponent, Microchip Technology and Masimo Feb 27 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)